Skip to main content
MYGNMyriad Genetics, Inc.Sell4.5·$5.57
MYGN · Why this verdict

Why Myriad Genetics (MYGN) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Myriad Genetics is a shrinking, unprofitable diagnostics company whose stock has rallied well above the analyst target, with falling estimates and a likely earnings test in 3 days making the rally hard to defend.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The stock at $6.35 is above the $3.90 analyst target, with a distance to target of -38.5% and a reward-to-risk of -2.57.

↑Improving
Analyst target
Expectation
Analyst targets should rise toward the price, or the price should retrace toward the target, over the next 12 months.

CounterThe price rally from momentum and rising on-balance volume may be telling us analysts are slow to update a target that has become stale.

Revenue is declining 10%, the Rule of 40 reads -8, and quality scores 3.5/10 with no competitive moat.

→Stable
Quality breakdown
Expectation
Revenue should return to growth above 0% and the Rule of 40 score should rise above 0 within 12 months.

CounterThe company is free-cash-flow positive despite a GAAP loss (FCF yield 3.0%) and gross margin scores 9.8/10, so the economics may be better than the loss suggests.

EPS missed in 2 of the last 3 reported quarters, the latest at -$0.25 against a -$0.06 estimate, and the next report is due in 3 days.

↓Deteriorating
Earnings
Expectation
EPS should come in at or better than estimates in the upcoming report and the following quarters.

CounterThe February report beat by $0.06 and surprise averages are skewed by small per-share numbers, so the misses may be noise.

Earnings estimates fell 5.1% over 30 days, and the sentiment score for the price target component is only 1.5/10.

↓Deteriorating
Catalyst breakdown
Expectation
Estimate revisions should turn positive within the next two quarters.

CounterEstimates fall before many turnarounds, and with institutions accumulating, lower expectations may set up easier comparisons.

The momentum score is 6.3/10 but RSI is 79 and the 200-day average slope is flat to negative, a late-stage rally with distribution risk.

↓Deteriorating
Momentum breakdown
Expectation
RSI should cool below 70 without the price falling below its 200-day average.

CounterOn-balance volume is rising and the MACD component is 9.9, showing buyers are still in control of the trend.

Per-dimension breakdown

Value

6.4/10data confidence 33%
ComponentSub-score
P/S9.9
Analyst target4.0

Quality

3.2/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin9.7
Op margin0.0
Net margin0.0
Current ratio6.9
FCF quality3.1
Moat4.8
Rule of 403.0
Piotroski F4.4
  • ▸FCF-positive despite GAAP loss (FCF margin 1%, FCF yield 0.9%)
  • ▸No competitive moat
  • ▸Rule of 40: -1 (fail)

Growth

2.1/10data confidence 33%
ComponentSub-score
Rev growth2.1
  • ▸Declining revenue: -2%

Momentum

3.1/10data confidence 100%
ComponentSub-score
RSI7.9
MACD1.4
OBV1.0
MA position5.0
Volume0.0
  • ▸Uptrend pullback (RSI 36) - buy opportunity
  • ▸Volume distribution (falling OBV)
  • ▸Above 200-MA but MA slope flat

Sentiment

5.9/10data confidence 100%
ComponentSub-score
LLM sentiment7.0
Analyst rating5.0
Price target5.9
  • ▸LLM news sentiment: +0.40 (n=1)

Insider

7.3/10data confidence 75%
ComponentSub-score
materiality5.0
holder change10.0
notable moves7.0
  • ▸No net insider activity — $0 (0.000% of mkt cap)
  • ▸Institutions accumulating

Peer rank

3.6/10data confidence 80%
ComponentSub-score
value rank9.7
quality rank1.3
growth rank1.0

Technical

6.2/10data confidence 100%
ComponentSub-score
bollinger7.7
support resistance7.9
52w position3.0
gap6.0

Risk (lower is worse)

4.5/10data confidence 100%
ComponentSub-score
short interest5.5
days to cover8.0
volatility0.0
put call0.0
max pain risk7.0
beta4.6
debt equity6.3
  • ▸Elevated put/call: 2.51

Catalyst

5.0/10data confidence 100%
ComponentSub-score
erm5.0
earnings history3.3
earnings timing5.0
surprise avg5.7
news activity6.0
  • ▸Earnings concerns: 2B/2M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (5)
  • INSIDER:OK
  • NEWS_BOOST:ANALYST:0.40
  • EARNINGS_PROXIMITY:99d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • MOMENTUM:3.1<4.5
  • ASYMMETRY:-0.6=NEGATIVE
Warning (1)
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.60
Upside
-7.8%
Downside
13.0%
Sizing output
AVOID

Setup— — No clear chart pattern; technical signals are mixed

EdgeNo clear edge — No clear edge identified

SuitabilityAggressive — Beta 1.61>1.3, MCap $0.5B<$5B

Investment implication

The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.1<4.5 outcome against Insider at 7.3 and asymmetric R:R of -0.60.

The strongest dimensions are Insider at 7.3, Value at 6.4, and Technical at 6.2; the weakest are Growth at 2.1, Momentum at 3.1, and Quality at 3.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -0.60 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Price Well Above Target

    Trip ifAnalyst target rises above $6.67 so that upside exceeds 5% from the current -38.5%.

  • P2Declining Revenue Weak Economics

    Trip ifRevenue growth exceeds 0% YoY versus the current -10%.

  • P3Earnings Misses Ahead Of Report

    Trip ifEPS surprise exceeds 0% for 2 consecutive quarters.

  • P4Falling Estimates

    Trip ifEarnings estimates rise more than 5% over 30 days, reversing the current -5.1%.

  • P5Overbought Rally Distribution Risk

    Trip ifMomentum score falls below 4.5 from the current 6.3 while the price drops more than 10%.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › MYGN › Why this verdict